Fig. 4From: DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patientsKaplan–Meier survival analysis for PFS and OS according to DDR gene mutation status. (A-B) Survival analysis of DDR mutations on the PFS in all NSCLC patients receiving platinum-based chemotherapy (A) and LUAD patients receiving platinum-based chemotherapy (B). (C-F) Survival analysis of DDR mutations on the PFS and OS in all NSCLC patients receiving platinum-based chemotherapy/immunotherapy (C-D) and LUAD patients receiving platinum-based chemotherapy/immunotherapy (E-F). PFS: progression-free survival, OS: overall survivalBack to article page